Medtech Clinical Trials Face Regulatory and Macro Shifts
The medical devices and medtech clinical trials industry faces a rapidly shifting landscape in 2026. Regulatory changes, funding pressures and emerging technologies are all converging at once. To address these challenges, industry leaders will gather at the Outsourcing in Clinical Trials: Medical Devices USA 2026 conference on June 2 and 3 in Minneapolis, Minnesota. The event brings together executives, researchers and innovators to discuss the most pressing opportunities and obstacles in the medtech sector today.
Overview of the OCT Medical Devices USA 2026 Conference
Setting the Stage for Industry Dialogue
The OCT Medical Devices USA 2026 conference opens with a broad examination of the forces reshaping the medical devices industry. Charlie Whelan, senior director of Consulting, Medical Devices at GlobalData, will deliver the opening talk. His presentation will cover macro-level trends across the medical devices sector. Furthermore, it will address the funding landscape for innovation amid larger macroeconomic pressures. This opening session sets the tone for two days of expert-led discussion and peer exchange.
Who Is Attending
The conference draws speakers and participants from across the medtech ecosystem. Companies including Philips, Agitated Solutions, Medtronic and the Clayton Sleep Institute have confirmed speaker representation on day one. Additionally, executives from Visura Technologies, Phenomix Sciences and Freyya are scheduled for day two. This breadth of participation reflects the cross-sector nature of the challenges the industry currently faces.
Macro Trends Shaping the Medtech Industry
The medtech sector does not operate in isolation. Broader economic conditions — including interest rate environments, geopolitical uncertainty and shifting investment priorities — directly affect how companies fund and execute clinical trials. Moreover, the regulatory environment has grown more complex. The FDA continues to evolve its expectations for medical device trials. Consequently, sponsors must adapt their strategies to satisfy both scientific and regulatory demands simultaneously. The OCT Medical Devices conference addresses this dual pressure directly, giving attendees practical frameworks to stay competitive.
Key Themes on Day One of the Conference
Lean Trial Protocols and Decentralized Elements
Day one presentations will cover several major themes relevant to medical device trials. Lean trial protocols represent one core focus area. Sponsors seek to reduce trial complexity and cost without compromising data quality. In addition, the implementation of decentralized elements — including remote monitoring, digital data capture and virtual site visits — continues to gain traction. These approaches allow trials to reach broader participant populations while reducing the burden on traditional clinical sites.
Device-Intensive Trials and Digital Workflows
Running device-intensive trials in specialty site networks presents unique operational challenges. Day one speakers will address how sponsors manage these complex environments effectively. Furthermore, digital workflows that account for the participant experience receive dedicated attention. Improving participant engagement and retention remains a top priority across the industry. Therefore, designing workflows around participant needs — not just operational convenience — is emerging as a core trial design principle.
Informed Consent and Participant Comprehension
A fireside chat with Serhii Zatsarynin, chief executive officer of Ovulio, will explore how sponsors can obtain meaningful informed consent while protecting participant comprehension. This balance is increasingly important as trials grow more complex and participant populations more diverse. Achieving genuine understanding — rather than simple checkbox compliance — requires thoughtful design of consent processes from the earliest stages of trial planning.
AI Integration in Medical Device Trials
Artificial intelligence is one of the defining themes of the 2026 medtech conference agenda. A dedicated panel of industry executives will discuss real-world use cases for AI adoption in medical device clinical trials. Rather than focusing on theoretical applications, the panel aims to provide a holistic view of where AI integration is actually happening today. Topics will likely span AI-assisted protocol design, patient matching, data monitoring and signal detection during active trials. The goal is to give attendees a grounded, practical understanding of where AI delivers genuine value — and where challenges remain.
Day Two: Early Strategy and Commercial Alignment
Aligning Research, Regulatory and Commercial Goals
The second day opens with a discussion on early strategic alignment. Executives from Visura Technologies, Phenomix Sciences and Freyya will join the conversation. Their talk examines how industry stakeholders can align on early research, regulatory and commercial strategies from the outset of a program. Misalignment between these functions remains a common source of delays and cost overruns in medtech development. Consequently, building coordination frameworks early in a program’s lifecycle is increasingly recognized as a competitive necessity. The session will also offer leadership guidance on how to drive productive collaboration across functions and organizations.
ePROs, Budget Planning and Real World Evidence
Digital Patient Reporting and Trial Budgets
Electronic patient-reported outcomes — known as ePROs — represent another key discussion topic on day two. ePROs allow sponsors to capture participant-reported data directly through digital platforms, reducing transcription errors and accelerating data availability. Moreover, clinical trial budget planning receives dedicated coverage. Cost pressures across the medtech industry make disciplined financial planning more critical than ever. Sponsors that build realistic, well-structured budgets early avoid costly mid-trial adjustments.
Leveraging FDA Real World Evidence Guidance
The FDA’s real world evidence guidance offers medtech sponsors new pathways to design fit-for-purpose trial strategies. Speakers will address how organizations can use this guidance practically to support regulatory submissions. Real world evidence draws on data from routine clinical practice — including claims data, electronic health records and patient registries — to complement traditional trial data. When used effectively, it can reduce trial size requirements, expand the evidence base and accelerate the path to approval.
Navigating the FDA’s QMSR Transition
One of the most significant recent developments in medical device regulation is the transition to the Quality Management System Regulation — known as QMSR. This FDA regulation covers manufacturing standards for medical devices and reflects a major update to longstanding requirements. The conference dedicates an interactive workshop to this topic, giving participants a structured opportunity to discuss the successes and challenges they have encountered since the transition took effect. The workshop format encourages candid peer exchange — a valuable complement to formal presentations.
For medtech companies still adapting to QMSR, the conference workshop offers practical insights from peers who have already navigated the transition. Understanding how others have addressed common compliance challenges can significantly accelerate an organization’s own adjustment process. Overall, the OCT Medical Devices USA 2026 conference provides a timely and comprehensive forum for the industry to collectively address the regulatory, technological and operational forces defining the medtech landscape in 2026.
